Telitacicept shows efficacy and tolerability over 39 weeks in part A of a phase 3 study in patients with IgA nephropathy. Telitacicept reduces proteinuria over 39 weeks compared with placebo with ...
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...
Like their causative mutations, pathophysiology and natural history, the clinical presentation of inborn errors of immunity (IEI) varies widely. Nevertheless, some features, above all recurrent and/or ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Chronic wound infections driven by multidrug-resistant (MDR) bacteria continue to ...
Background: Early diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers for lung ...
The following is a summary of “Kinetics of tick-borne encephalitis virus IgM antibody responses in serum and cerebrospinal fluid,” published in the March 2025 issue of Infectious Diseases by Morgardt ...
BHV-1300 reduced total IgG by up to 84% in a four-week Phase 1 study. The treatment was well-tolerated, with no serious adverse events reported. Get access to the leaderboards pointing to tomorrow’s ...
Researchers hope someday the vaccine will allow people with celiac disease to have gluten in their diets ...
NEW YORK — Werfen said Monday that it has received US Food and Drug Administration 510(k) clearance for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback